Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab

NCT06287229 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Relapsed/Refractory
B-cell Acute Lymphocytic Leukemia

Interventions

DRUG: Blinatumomab
DRUG: Inotuzumab Ozogamicin
DRUG: Hyper-CVAD
DRUG: Mini-hyper-CVD

Sponsor

M.D. Anderson Cancer Center